modelAlbendazole_1
Extends from Pharmacolibrary.Drugs.ATC.P.P02CA03_1.
Information
| name: | Albendazole_1 | |
| ATC code: | P02CA03_1 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 0.8 | L |
| clearance: | 0.42 | L/h/kg |
| other parameters in model implementation | ||
Albendazole is an anthelmintic drug used to treat a broad range of parasitic worm infestations, including neurocysticercosis, hydatid disease, giardiasis, and soil-transmitted helminthiases. It disrupts the microtubule formation in parasites, leading to their immobilization and death. Albendazole is widely approved and used globally for these indications.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers after a single 400 mg oral dose, co-administered with a fatty meal.
References
Whittaker, C, et al., & Boussinesq, M (2022). Factors associated with variation in single-dose albendazole pharmacokinetics: A systematic review and modelling analysis. PLoS neglected tropical diseases 16(10) e0010497–None. DOI:10.1371/journal.pntd.0010497 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36306320
Fimbo, AM, et al., & Aklillu, E (2023). Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania. CPT: pharmacometrics & systems pharmacology 12(12) 1884–1896. DOI:10.1002/psp4.13038 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37638539
Pettarin, M, et al., & Kostewicz, ES (2020). A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base albendazole and its main metabolite albendazole sulfoxide. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 155 105552–None. DOI:10.1016/j.ejps.2020.105552 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32937212
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)